Fecal Microbiota Transplantation for Patients With Chronic Widespread Pain

This study aims to explore the effect of Fecal Microbiota Transplantation (FMT) on the clinical symptomatology in Chronic Widespread Pain (CWP), to assess the acceptability, tolerability, and safety of FMT in patients with CWP, as well as explore the effect of FMT on the gut microbiome diversity in CWP. The investigators hypothesize that fecal microbiota transplantation will reduce pain intensity in patients with CWP, is acceptable, safe, and tolerable in patients with CWP, and will achieve change of gut microbiome diversity after FMT treatment.

Inclusion Criteria:• Participants aged ≥ 18 with diagnosis CWP; A modified version of the London Fibromyalgia Epidemiology Study Screening Questionnaire (LFESSQ) will be used to screen for the presence of CWP.Exclusion Criteria:Patients with fibromyalgia, a subgroup with complex neurobiological, behavioural and psychological factors on its pathogenesis, will be excluded.[8] This will be based on The American College of Rheumatology 2010 when subjects with CWP but with a widespread pain index (WPI) of ≥ 7 and a symptom severity scale (SSS) score of ≥ 5 or a WPI between 3 and 6 and an SSS score of ≥ 9.Patients have a history of inflammatory bowel disease or gastrointestinal malignancyPatients have previous abdominal surgery (other than cholecystectomy or appendectomy)Patients have depression defined by having a Patient Health Questionnaire-9 (PHQ-9) score > 15Patients have anxiety defined by having a Generalized Anxiety Disorder 7 (GAD7) score > 10Patients have active infection at the time of inclusionPatients have used antibiotic therapy or anti-inflammatory drugs within the past 7 daysPatients have any other organic causes that can explain the symptoms of CWPCurrent pregnancyConfirmed current active malignancy or cancersPregnancy test negative for all female patients of child-bearing potential (except postmenopausal patients and sterilized patients).